Lusutrombopag
 | |
| Clinical data | |
|---|---|
| Trade names | Mulpleta |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C29H32Cl2N2O5S |
| Molar mass | 591.54 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  | |
Lusutrombopag is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures. It is being manufactured and marketed in Japan by Shionogi under the trade name Mulpleta.[1][2][3] It was approved by FDA in July 2018.[4]
References
- ↑ Shionogi Receives Marketing and Manufacturing Approval in Japan for MULPLETA® Tablets 3mg for Improvement of Thrombocytopenia, September 28, 2015
- ↑ Shionogi Launches MULPLETA® Tablets 3mg In Japan for Improvement of Thrombocytopenia
- ↑ Lusutrombopag (MULPLETA) for severe thrombocytopenia in patients with chronic liver disease undergoing an elective invasive procedure
- ↑ "FDA approves lusutrombopag for thrombocytopenia in adults with chronic liver disease". Food and Drug Administration. July 31, 2018.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.